Online citations, reference lists, and bibliographies.

Inflammation And The Etiology Of Type 2 Diabetes.

Åke Sjöholm, Thomas Nyström
Published 2006 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Type 2 diabetes is increasingly common worldwide and is beginning to strike younger age groups. Almost 90% of all patients with diabetes show insulin resistance, which also precedes the first symptoms of diabetes. The mechanisms underlying the development of insulin resistance are not well understood. In recent years, several studies have been published that implicate subclinical chronic inflammation as an important pathogenetic factor in the development of insulin resistance and type 2 diabetes. This opens new perspectives for diagnosis and treatment of early insulin resistance and incipient glucose intolerance. Surrogate markers for this low-grade chronic inflammation include CRP, IL-6 and TNF-alpha. Some antidiabetic agents, for example, glitazones that reduce insulin resistance, and insulin itself, reduce inflammation. Conversely, antiinflammatory drugs (ASA/NSAID) may improve glucose tolerance. Vasoactive drugs that are often prescribed to people with diabetes, for example, statins and ACE inhibitors/angiotensin receptor antagonists, also counteract inflammation and reduce the risk of type 2 diabetes. More specific and sensitive biomarkers should be identified, which may predict early disturbances in insulin sensitivity and cardiovascular risk. Also, inflammatory signalling pathways need to be explored in greater detail, and may form the basis of drugable targets against the epidemic of insulin resistance and atherosclerosis.
This paper references
Beyond blood pressure: the endothelium and atherosclerosis progression.
Ernesto L Schiffrin (2002)
Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women.
A. Elisabeth Hak (1999)
Inflammation: the link between insulin resistance, obesity and diabetes.
Paresh Dandona (2004)
Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
Lars Lindholm (2003)
Hypothesis: PGE, Carbohydrate Homeostasis, and Insulin Secretion: A Suggested Resolution of the Controversy
Ronald P. Robertson (1983)
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Lars Lindholm (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
Heart Protection Study Collaborative Group (2002)
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.
Aruna D. Pradhan (2001)
Global and societal implications of the diabetes epidemic
Paul Z. Zimmet (2001)
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
Salim Yusuf (2003)
The Insulin Resistance Atherosclerosis Study Family Study
Carl D. Langefeld (2004)
C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998.
Barbara Thorand (2003)
Minireview: adiposity, inflammation, and atherogenesis.
Christopher J. Lyon (2003)
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.
Haiyan Xu (2003)
Differential effects of cytokines on long-term mitogenic and secretory responses of fetal rat pancreatic beta-cells.
Ake Sjoholm (1992)
Low-grade systemic inflammation and the development of type 2 diabetes mellitus [ndash] : the ARIC Study
Bruce Bartholow Duncan (2003)
Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis.
Sashant Navalkar (2001)
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Marc Pfeffer (2003)
Is Type II diabetes mellitus a disease of the innate immune system?
John C Pickup (1998)
Prevention of primary nonfunction of canine islet autografts by treatment with pravastatin.
Seiji Arita (2002)
Modulation of the inflammatory process by statins.
Milita Crisby (2003)
Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure Insight From the Studies Of Left Ventricular Dysfunction (SOLVD)
Emmanuelle Vermes (2003)
Nyström in hypertension : the Captopril Prevention Project ( CAPPP ) randomised trial
S Yusuf (1999)
The prognostic value of the electrocardiogram in the west of Scotland coronary prevention study
Peter W. Macfarlane (2002)
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.
Andreas Festa (2002)
Inhibition of tumor necrosis factor-alpha with anti-diabetic agents.
Masahiro Fukuzawa (1999)
Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.
Toshihiko Yada (1999)
Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).
Anne Festa (2000)
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Lennart Hansson (1999)
Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans.
Shuhei Nakanishi (2003)
Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ
Mike Yuan (2001)
People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
Robert M. Califf (2003)
Prostaglandins, glucose homeostasis, and diabetes mellitus.
Ronald P. Robertson (1981)
Peroxisome proliferator-activated receptors in inflammation control.
Philippe Delerive (2001)
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Giovanni Battista John Mancini (2002)
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk
Stevo Julius (2003)
Do atherosclerosis and type 2 diabetes share a common inflammatory basis?
Aruna D. Pradhan (2002)
Adipocytokines and insulin resistance.
Anastassios G. Pittas (2004)
Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action.
Paresh Dandona (2003)
Clinical significance of pleiotropic effects of statins: lipid reduction and beyond.
Johann Auer (2002)
Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.
J Berger (2001)
Angiotensin blockade prevents type 2 diabetes by formation of fat cells.
Arya M. Sharma (2002)
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
Laurence Duplomb (2004)
Prostaglandins inhibit pancreatic beta-cell replication and long-term insulin secretion by pertussis toxin-insensitive mechanisms but do not mediate the actions of interleukin-1 beta.
Åke Sjöholm (1996)
Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian.
Jonathan Krakoff (2003)
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
Salim Yusuf (2000)
The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes.
Paresh Dandona (2003)
Treating type 2 diabetes - today's targets, tomorrow's goals.
Kurt George Matthew Mayer Alberti (2001)
- Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Paul M. Ridker (1999)
Inflammation and insulin resistance.
Zachary T Bloomgarden (2003)
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Marc Pfeffer (2003)
Insulin resistance and chronic cardiovascular inflammatory syndrome.
José-Manuel Fernández-Real (2003)
A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis.
Paresh Dandona (2002)
Prostaglandins as modulators of pancreatic islet function.
Ronald P. Robertson (1979)
Anti-inflammatory and immunomodulating properties of statins
Pier Luigi Meroni (2002)
C-reactive protein is independently associated with fasting insulin in nondiabetic women.
Aruna D. Pradhan (2003)
Activation of the hypothalamic-pituitary-adrenal axis in obesity: cause or consequence?
Brian Robert Walker (2001)
Atherothrombosis, inflammation, and diabetes.
Giuseppe Biondi-Zoccai (2003)
C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?
John S. Yudkin (1999)
Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease.
Samy McFarlane (2003)
Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study☆
Michelle Asha Albert (2001)
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study.
Thang S. Han (2002)
No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients.
Nicolas Paquot (2000)
Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.
Ram D Pathak (2002)
PPARs in Inflammation, Atherosclerosis and Thrombosis
Hélène Duez (2001)
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study.
Dilys J. Freeman (2002)
Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
G Locci (2001)

This paper is referenced by
Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats.
Zhen Huang (2008)
Effects of sleep fragmentation on glucose metabolism in normal subjects.
Katherine A. Stamatakis (2010)
Prenatal psychosocial stress exposure is associated with insulin resistance in young adults.
Sonja Entringer (2008)
Diabetes Pathogenesis - Role of Natural Killer Cells, T Cells and a Novel Neuropeptide
Hanna Brauner (2010)
Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment
Xiaohua Li (2015)
Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes.
Johanna Weigert (2010)
Polymorphisms of MMP-3 and TIMP-4 genes affect angiographic coronary plaque progression in non-diabetic and type 2 diabetic patients.
Qiu Jing Chen (2009)
Chlamydia antibodies and self-reported symptoms of oligo-amenorrhea and hirsutism: a new etiologic factor in polycystic ovary syndrome?
Laure C Morin-Papunen (2010)
Adverse Childhood Experiences among a Community of Resilient Centenarians and Seniors: Implications for a Chronic Disease Prevention Framework.
Rhonda Spencer-Hwang (2018)
Effect of periodontitis on insulin resistance and the onset of type 2 diabetes mellitus in Zucker diabetic fatty rats.
Keiko Watanabe (2008)
Inflammatory Markers in Obese Adolescents with Type 2 Diabetes and Their Relationship to Hepatokines and Adipokines.
Thomas Reinehr (2016)
Discovery of Novel Anti-Diabetic Drugs by Targeting Lipid Metabolism.
Xiu Zhou (2015)
Diabetes drugs and neurological disorders: new views and therapeutic possibilities.
Cesare Patrone (2014)
Adipocinas y síndrome metabólico: múltiples facetas de un proceso fisiopatológico complejo Adipokines and metabolic syndrome: multiple aspects of a complex pathophysiological process
Julio C. Sánchez (2010)
Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies.
Giuseppe Derosa (2013)
Las adipocinas como mediadoras en la inflamación y el sistema inmune
Carlos Alejandro Nava-Santana (2013)
Estimation of vitamin E level and its relation to lipid profile in patients with type II Diabetes Mellitus
Ihsan Mahmood (2015)
Vitamin D deficiency in gestational diabetes mellitus and the role of the placenta.
Geum Joon Cho (2013)
Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes.
Hauwa’u Yakubu Bako (2019)
Chemerin Isoforms and Activity in Obesity
Christa Buechler (2019)
A Histomorphometric Study on the Neurohypophysis of STZ-induced Diabetic Albino Rats
Muhamed Faizal (2018)
Macrotyloma uniflorum (Lam.) Verdc. improves glucose metabolism and proinflammatory parameters in high fructose fed rats
Veerappan Ramanathan (2019)
Resistin increases islet blood flow and decreases subcutaneous adipose tissue blood flow in anaesthetized rats.
Tage Danielsson (2009)
Exploratory Studies of Microbiome Dysbiosis and Plasticity in Mice and Humans
Xin Zhou (2019)
Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise.
Paul W Bodell (2009)
The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice.
Ryan P. Ceddia (2016)
What is the frequency of carbohydrate metabolism disorder in CKD?
Taner Basturk (2012)
Increased systemic inflammation and altered distribution of T-cell subsets in postmenopausal women
Julie Rafn Abildgaard (2020)
Addition of Inflammatory Biomarkers Did Not Improve Diabetes Prediction in the Community: The Framingham Heart Study
Dhayana Dallmeier (2012)
The role of socioeconomic stress in the risk for obesity and diabetes: potential new targets of treatment
Amber M. Healy (2010)
Zhen Huang (2007)
Protection against stroke with glucagon‐like peptide 1 receptor agonists: a systematic review and meta‐analysis
Fotios Barkas (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar